Pangaea Oncology

12/08/2025

If you're looking for a single partner with the capabilities to drive projects across every phase, contact our Business Development team: info@panoncology.com 📩

At Pangaea Oncology, we provide a unique ecosystem that integrates research, diagnostics, clinical trials, and patient care under one roof. This end-to-end model empowers pharmaceutical partners to move faster and smarter through every phase of oncology development. 🔬💊🏥

Our services are structured to support every key moment in the development pipeline: discovery and validation, clinical ex*****on, and real-world implementation. Each phase builds naturally into the next, with aligned, first-quality teams. 👨‍⚕️👩‍🔬

Our integrated operating model allows and companies to progress through discovery, validation, and implementation without changing partners at every step.

The depth of our technical expertise is supported by recognized accreditations and years of collaboration with leading research programs and clinical networks. Every project is handled by specialists who understand both the science and its clinical implications. 🤝

By operating within hospitals, we provide direct access to patients, samples, and clinical data. This accelerates trial readiness and shortens the distance between hypothesis and results. ⌛

With Pangaea, there is no need to coordinate across separate providers. From bench to bedside.

04/08/2025

Global Thought Leadership in Action, Dr. Rosell at PULCOR 2025 🌎

This week, Dr. Rafael Rosell, President of Pangaea Oncology and Head of the Scientific Committee, will participate in a high-level international event that reinforces his ongoing dedication to driving innovation in lung cancer treatment. 🫁

On August 7th, Dr. Rosell will take part in 2025, a key congress on pulmonary diseases and thoracic oncology led by Dr. Eduardo Richardet in . He will join the dedicated module on KRAS-targeted therapies in lung cancer, bringing the latest insights from the front lines of precision oncology. 🔍

This appearance highlights Dr. Rosell’s unwavering commitment to advancing cancer research and his active involvement in the global scientific community. His presence at PULCOR is yet another example of how leading clinician-scientists continue to shape the future of , not only by applying existing treatments, but by continuously seeking better solutions for patients.

🤝 At Pangaea Oncology, we believe that research and clinical care must go hand in hand. Dr. Rosell exemplifies this vision through his dedication to discovery, collaboration, and the relentless pursuit of progress.

29/07/2025

Want to work with a partner committed to transforming the future of cancer through science and innovation? Contact our Business Development team and let’s explore how we can do it: info@panoncology.com 📥

At Pangaea Oncology, everything we do is driven by a clear , a forward-looking , and a set of that guide our daily practice. These principles shape how we care for patients, engage with science, and collaborate with the healthcare ecosystem. 🤝

So far, we've built highly specialized teams, developed leading-edge technologies, advanced scientific knowledge and forged strong collaborations with the pharmaceutical industry. We aim to continue delivering this excellence by expanding our impact, reaching more patients and helping to change the future of cancer. 👩‍⚕️🔍🔬

If you share this vision and want to be part of it, don’t hesitate to reach out.

21/07/2025

Looking for a strategic clinical partner to accelerate your clinical trials? Our Business Development team is here to help: info@panoncology.com 📥

Our approach to cancer care is based on subspecialized expertise, scientific integration, and proximity to the patient. That means being present as embedded clinical teams within top hospitals, working side by side with local services to deliver precision oncology in practice. 🏥

Catalunya is internationally recognized as a leading hub for oncology, with a high concentration of clinical expertise 🩺, research institutions 🔍, and scientific innovation. 🧬

Our presence across key hospitals in the region allows us to be an active part of this ecosystem, bringing science into daily clinical practice and ensuring patients have access to the most advanced personalized care through our specialized medical units. 👨‍⚕️👩‍⚕️

You can find us at:
🏥 Hospital Quirónsalud Barcelona
🏥 Hospital Quirónsalud Badalona
🏥 Hospital El Pilar (Barcelona)
🏥 Centro Médico Teknon (Barcelona)
🏥 Hospital Universitari Dexeus (Barcelona)
🏥 Hospital Universitari General de Catalunya (Sant Cugat del Vallès)
🏥 Hospital Universitari Sagrat Cor (Barcelona)

01/07/2025

📄 The Lancet eClinicalMedicine has published the study “Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer”, featuring several of our specialists as co-authors:

🥼🥼 Dr. Alejandro Martínez-Bueno and Dr. Xavier González i Farré (IOR)
🥼🥼 Dr. José Manuel Pérez García and Dr. Javier Cortés (IBCC)

🔎 The study investigates a proactive approach to mitigate two of the most common and treatment-limiting side effects of sacituzumab govitecan: neutropenia and diarrhea. Both toxicities can significantly impact patient outcomes and adherence in HER2-negative advanced breast cancer.

👉 By introducing G-CSF and loperamide as primary prophylaxis (preventive treatment given before symptoms appear) from the first cycle, the trial demonstrated a lower incidence of severe toxicity compared to historical data, supporting a more tolerable and sustainable use of the drug in clinical practice.

This contribution reflects a central challenge in precision oncology: not only developing the most effective therapies, but making them safer and more manageable for patients, reducing toxicities and preserving quality of life both during and after treatment.

🔗 Full study in The Lancet eClinicalMedicine:

25/06/2025

📄 We are proud to share the recent publication in Nature Medicine of the study “Atezolizumab plus bevacizumab and weekly paclitaxel for untreated locally advanced or metastatic triple-negative breast cancer (ATRACTIB): a phase 2, single-arm trial”, featuring three of our specialists as co-authors:

🥼 Dr. Alejandro Martínez-Bueno (Instituto Oncológico Dr. Rosell)
🥼🥼 Dr. Javier Cortés and Dr. José Manuel Pérez (IBCC - International Breast Cancer Center)

🔎 The study addresses one of the most challenging forms of (triple-negative breast cancer), known for its rapid progression and limited targeted treatment options.

👉 The trial tested a combination of atezolizumab, paclitaxel, and bevacizumab, achieving an objective response rate of 67.3% and clinical benefit in 78.8% of patients, regardless of PD-L1 status, which could suggest broader treatment eligibility than current approvals.

👉 Another key takeaway: the treatment was reported as well tolerated, with manageable side effects, which is especially relevant in TNBC where therapeutic intensity often leads to high toxicity.

These results open the door to new therapeutic strategies in a setting with limited alternatives. It’s a step forward for research, and for patients who urgently need more effective options.

🔗 Full study in Nature Medicine:

A single-arm phase 2 trial in patients with mostly PD-L1-negative advanced triple-negative breast cancer shows that treatment with the anti-PD-L1 agent atezolizumab, paclitaxel and the anti-VEGF agent bevacizumab prolongs progression-free survival.

24/06/2025

🫁 Respiratory Health stands out as the leading center in clinical trials for respiratory diseases, built on long-term collaborations with top global pharmaceutical companies and backed by deep biomedical expertise.

It drives the development of pioneering, ground-breaking treatments with precision and scale. This expertise extends beyond science to include the operational discipline required to manage complex trials efficiently.

Streamlined workflows, high patient retention, and robust systems for data traceability and security position Pectus as a reference in clinical ex*****on. 🔍

With over 6,500 visits conducted, the center ensures real access to innovation for patients while maintaining consistency in care and research quality. 🤝

Its infrastructure, scale, and reliability make it a strategic partner of choice for advancing respiratory health through clinical research. 🔬

19/06/2025

THE DRIVING FORCE BEHIND PANGAEA: Specialized Patient Care 🩺

At Pangaea, we believe that hyper-specialization is essential to deliver truly effective oncology. Each cancer type demands a specific approach, and our structure ensures patients are treated by experts focused exclusively on their disease. 🥼

🏥 Our institutions work as a connected ecosystem, covering breast, lung, head and neck, digestive, genitourinary, CNS tumors and more, across all stages, from diagnosis to advanced treatment, clinical trials, and continuous care.

Our medical team bridges daily patient care with a strong scientific foundation, constantly engaging in top global cancer and pneumology congresses and clinical research meetings. 🔍🔬📚

They don’t just keep up, they lead. Many of our specialists are recognized among the world’s top leaders in their fields by the most respected international rankings and associations. Their presence in major publications, advisory boards, and research networks reflects this scientific commitment that precision medicine demands. 🤝

30/05/2025

EUROPEAN WEEK AGAINST CANCER 🌍🩹
LISTENING. TREATING. CARING.

LUNG CANCER, IN FOCUS 🔍

To close the European Week Against Cancer, we turn our attention to one of the most complex and prevalent cancer types. Through the voice of a Pangaea expert, we reflect on the current challenges and breakthroughs shaping the future of lung cancer care. 🫁

is the leading cause of cancer-related deaths in and worldwide. Despite years of research, many cases are still diagnosed at advanced stages. But thanks to early detection strategies, molecular profiling, and the integration of innovative tools, a new era of more personalized and effective care is emerging. 🩺

We hope this week has helped bring the reality of cancer care closer to many people, serving as a bridge to better understand the work that takes place every day, not just during this week.

There is much that has been achieved, and still much to be done, but what matters most is that we’re moving in the right direction — and this is a challenge no one faces alone. 💜

29/05/2025

EUROPEAN WEEK AGAINST CANCER 🌍🩹
LISTENING. TREATING. CARING.

UROLOGIC CANCERS, IN FOCUS 🔍

Cancer is the second leading cause of death in the European Union — a reality that continues to drive innovation, early detection, and the pursuit of more effective, personalized treatments. During the European Week Against Cancer, we continue our series of expert insights from the Pangaea ecosystem, focusing on the evolving landscape of care and the progress that sustains our collective effort. 🤝

Urologic cancers include a diverse group of diseases — from prostate, kidney, and bladder cancer to more uncommon tumors like testicular or pe**le cancer. Prostate cancer alone is the most frequently diagnosed tumor in men in Spain. 🧔‍♂️

While remarkable progress has been made in personalized treatment and immunotherapy, the landscape remains complex, and prevention and early detection are still critical tools we must strengthen. 🏥

This week is about standing closer to patients, to the medical community, and to one another. It’s about offering answers, building trust, and working each day with the conviction that medicine is moving us closer to a future where solutions are within reach for everyone.

28/05/2025

EUROPEAN WEEK AGAINST CANCER 🌍🩹
LISTENING. TREATING. CARING.

GYNECOLOGIC CANCERS, IN FOCUS 🔍

As part of the European Week Against Cancer, we continue our series of expert reflections from the Pangaea ecosystem. Each day, we highlight a different cancer type through the voice of one of our specialists, exploring today’s challenges, tomorrow’s advances, and the values that guide our work.

Gynecologic cancers account for nearly 15,000 new diagnoses each year in Spain. They represent a major area of focus in women’s oncology and include some of the most preventable and treatable tumor types, as long as early detection and access to innovation are ensured. 🩺🔬

This week invites us to reflect not only on how far we’ve come, but on the work still needed to ensure that innovation, prevention, and quality care reach every patient. It’s a time to listen more closely, act more precisely, and strengthen the connections that bring meaningful solutions within everyone’s reach. 🤝

27/05/2025

EUROPEAN WEEK AGAINST CANCER 🌍🩹
LISTENING. TREATING. CARING.

BREAST CANCER, IN FOCUS 🔍

Throughout the European Week Against Cancer, we’re dedicating each day to one specific cancer type, sharing insights from experts within the Pangaea ecosystem. These conversations reflect our commitment to understanding challenges, highlighting progress, and staying close to what matters most: people. 🤝

Breast Cancer is the most common tumor among women in , with nearly 35,000 new cases diagnosed each year. Thanks to early detection and continuous innovation in treatment, survival rates have steadily improved. But behind every statistic, there’s a patient — and the journey still demands ongoing advances in quality of life and personalization. 🩺

This week is about connection, clarity, and conviction. It’s about listening better, treating smarter, and caring deeper — all while working toward a future where solutions are possible and accessible to all.